CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grimison, B.
Right arrow Articles by Sclafani, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grimison, B.
Right arrow Articles by Sclafani, R. A.
Cell Growth & Differentiation Vol. 11, 507-515, October 2000
© 2000 American Association for Cancer Research


Articles

p16Ink4a Tumor Suppressor Function in Lung Cancer Cells Involves Cyclin-dependent Kinase 2 Inhibition by Cip/Kip Protein Redistribution1

Bryn Grimison, Thomas A. Langan and Robert A. Sclafani2

University of Colorado Comprehensive Cancer Center and Department of Biochemistry and Molecular Genetics [B. G., R. A. S.] and Department of Pharmacology [T. A. L.], University of Colorado Health Sciences Center, Denver, Colorado 80262

Abstract

As cell cycle regulators whose activity is frequently altered in human cancers, cyclin-dependent kinases (cdks) are novel targets for therapeutic intervention. cdk inhibition is an emerging strategy for the treatment of non-small cell lung carcinomas (NSCLCs) because most derived cell lines express functional retinoblastoma protein (Rb) but appear to bypass its function with inappropriate cdk activity. Elevated cdk4/cdk6 activity in NSCLC cells is often due to inactivation of the p16Ink4a cdk inhibitor. To model the effects of cdk4/cdk6 inhibition, we have expressed p16Ink4a in a Rb-positive NSCLC cell line that lacks endogenous p16Ink4a expression. Whereas cdk4/cdk6 inhibition and Rb dephosphorylation are expected on p16Ink4a expression, we have also observed indirect cdk2 inhibition. cdk2 inactivation by the redistribution of other cdk inhibitors may be required for p16Ink4a-mediated growth suppression of Rb-positive cells. The implications of such a requirement on the use of chemical cdk inhibitors to treat human cancers will be discussed.




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. Solodushko and B. Fouty
Proproliferative phenotype of pulmonary microvascular endothelial cells
Am J Physiol Lung Cell Mol Physiol, March 1, 2007; 292(3): L671 - L677.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
G. S. Shapiro, C. Van Peursem, D. A. Ornelles, J. Schaack, and J. DeGregori
Recombinant Adenoviral Vectors Can Induce Expression of p73 via the E4-orf6/7 Protein
J. Virol., June 1, 2006; 80(11): 5349 - 5360.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. Tyagi, R. P. Singh, C. Agarwal, S. Siriwardana, R. A. Sclafani, and R. Agarwal
Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells
Carcinogenesis, November 1, 2005; 26(11): 1978 - 1987.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. H. Box and D. J. Demetrick
Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines
Carcinogenesis, December 1, 2004; 25(12): 2325 - 2335.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Benzeno, G. Narla, J. Allina, G. Z. Cheng, H. L. Reeves, M. S. Banck, J. A. Odin, J. A. Diehl, D. Germain, and S. L. Friedman
Cyclin-Dependent Kinase Inhibition by the KLF6 Tumor Suppressor Protein through Interaction with Cyclin D1
Cancer Res., June 1, 2004; 64(11): 3885 - 3891.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Jiang, C. B. Matranga, D. Cai, V. M. Latham Jr., X. Zhang, A. M. Lowell, F. Martelli, and G. I. Shapiro
Flavopiridol-Induced Apoptosis during S Phase Requires E2F-1 and Inhibition of Cyclin A-Dependent Kinase Activity
Cancer Res., November 1, 2003; 63(21): 7410 - 7422.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2000 by the American Association of Cancer Research.